Evidence Europe 2017 Speakers
Mahmood Adil, Medical Director, Information Services Division (Scotland) and Health Protection Scotland, NHS National Services Scotland
Omar Ali, Member of Adoption and Impact Programme Reference Panel, National Institute for Health and Care Excellence
Anna Bucsics, External Lecturer, MoCA board member, University of Vienna
Mr Bill Byrom, Senior Director of Product Innovation, Icon
Sue has have more than 18 years international experience working in the fields of market access, health economics, pricing, and policy in the areas of academia, government and the pharmaceutical industry. She has worked in Europe, Australia, Singapore and since Nov 2015, the United States. During...
Sue Caleo-Naeyaert, Global Head Pricing, Market Access and Policy Biosimilars, EMD Serono
Francesca Caprari, Head of Payer Intelligence and HTA, Global Market Access, Sanofi-Aventis S.p.A
Mrs Lisbet Coulton, Managing Director, Tanwood Consulting
Carla Deakin, Associate Director, Office for Market Access, NICE
Mr Hans Peter Frank, Global Head of Integrated Solutions, Vifor Fresenius Medical Care Renal Pharma Ltd
Sarah Gorst, , University of Liverpool
Dr Alicia Granados is since 2011 Head of Global Health Technology Assessment (HTA) Scientific Strategy atSanofi Genzyme, company based in Cambridge, Massachusetts. The mission of her department is contributing to improve the effectiveness and efficiency of Sanofi Genzyme clinical research...
Dr Alicia Granados MD,PhDPH, Head of Global Health Technology Assessment, POME- Global Medical Affairs, Genzyme
Alex Grosvenor is a Senior Principal at Precision for Value, where he leads the EU arm of the Global Product Pricing & Strategy practice, based in London. Alex is a seasoned pricing and market access consultant in the biopharmaceutical industry. He has significant experience in rare...
Mr Alexander Grosvenor, Senior Principal of Global Pricing and Market Access, Precision for Value
Neil Grubert, Global Market Access Consultant, Independent
Ms Rachelle Harris, Policy Adviser, Access To Medicines, D.F.I.D.
Bertram Häussler is the chairman of the IGES Group, a corporation of research and consulting companies specializing in infrastructure and health care. He is a medical doctor, sociologist, and honorary professor of Economics of the Pharmaceutical Industry at the Technical University (TU) Berlin. His ...
Mr Bertram Haussler, Chairman of the Board, I.G.E.S. Institut Gmbh
Mr Ansgar Hebborn, Head of Global H.T.A. and Payment Policy, F. Hoffman- La Roche Ag
Patrick is Executive Director World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol Myers Squibb. He leads the team responsible for supporting country HTA submissions and access. He is responsible for all countries outside of the US. Patrick also leads WWHEOR HTA Policy...
Mr Patrick Hopkinson, Executive Director, WWHEOR Markets, Bristol Myers Squibb
A self-described “data nerd,” Ashley’s mission is to formulate and implement the Context Matters’ analytical strategic plan. Early on, Ashley defined all of the original key variables and categories that would become the signature of Context Matters’ commitment to drilling down into great detail to ...
Ms Ashley Jaksa, Vice President of Data and Analytics, Context Matters Inc
Ravi Jandhyala, Chief Medical Officer, RWE Genesys
Professional career developed in governmental institutions in the Brazilian Healthcare System, R&D and HTA. Master and PhD in Internal Medicine and Health Economics. Currently responsible for Reimbursement, Pricing and HEOR at Shire Brazil.
Marcela Junqueira, Head of Value Demonstration and Access, Shire Farmacêutica Brasil Ltda
Ms Marie Kane, Chief Operating Officer, NorthWest EHealth
Adam is a Senior Global Payer Strategy Manager working in oncology pipeline at Boehringer Ingelheim. He is managing global pricing and market access strategies for the oncology portfolio and driving the development of innovative market access approaches and payment schemes. Since September 2015 he...
Adam Kundzewicz, Senior Global Payer Strategy Manager, Head of Pricing, Boehringer Ingelheim Pharma GmbH & Co. KG
Ms Christine Lavery, Chief Executive Officer, MPS Society
François Luca, Principal Consultant, POPE WOODHEAD AND ASSOCIATES LIMITED
Mr Donald Macarthur, Director, DM Pharma Issues Ltd
Jörg Mahlich graduated in economics from the University of Kiel/Germany and holds a doctoral degree in economics from the University of Vienna/Austria. He is currently heading the health economics department at Janssen Japan in Tokyo. Previous to that he was in the market access team of Janssen...
Mr Joerg Mahlich, Director Health Economics, Janssen Pharmaceutical K.K.
Dr Anne Marciniak, Senior Director, International HEOR, Allergan
Goran earned his Masters of Pharmacy degree at the Faculty of Pharmacy, University of Belgrade in Serbia and specialised in pharmacoeconomics and pharmaceutical legislation. He has more than 9 years of hands-on experience in performing systematic literature reviews, meta-analysis, writing...
Goran Medic, Market Access Manager Europe, Horizon Pharma
Ms Nazanin Mehin, Global head of Cardiovascular Value & Access, Sanofi
Mr Nick Merryfield, Partner, Stisali
Dr. François Meyer is currently Advisor to the President of the French National Authority for Health (HAS, Haute Autorité de Santé), with a particular focus on International Affairs. He is a member of the board of HTAi, the international professional society for HTA, and INAHTA, the international...
Mr Francois Meyer, Advisor To The President, Haute Autorite De Sante
Ms Susanne Michel, Vice President of Practice Lead of Payer Strategy, Evidera
Thomas Mueller is Medical Doctor and Pharmacist. He completed his studies in Berlin and London, and then worked in the Dermatology Department of the University Hospital Charité Berlin. He completed postgraduate studies in business administration. Subsequently, he worked for several years in the...
Dr Thomas Mueller, Head of Pharmaceuticals, G-BA
Dr Melvin "Skip" Olson, Global Head RWD Strategy and Innovation, Novartis Pharma
Dr Melvin "Skip" Olson, Global Head RWD Strategy and Innovation, Novartis Pharma
Nektarios (Aris) Oraiopoulos is a faculty member at the Judge Business School, University of Cambridge. His research and teaching activities are focused on how firms can improve their new product development processes from the creation of new opportunities to the selection process to the...
Aris Oraiopoulos, Pharmaceutical Researcher, Cambridge Judge Business School
Mauro Patroncini, Pipeline Product Strategy Leader, Roche
Klaas Postema, Senior Director Market Access & Pricing Generics Europe, Teva
Malcolm qualified in 1984 with BSc in Pharmaceutical Sciences, gained a Masters in 1987 and ILM Certificate in Hospital Management in 2002. He has worked at Royal Liverpool, St James Leeds and Leicester Royal Infirmary now part of University Hospitals of Leicester. His current post is Pharmacy...
Malcolm Qualie, Pharmacy Lead for Specialised Services, NHS England
Mr James Robinson, Director, Industry Solutions for Europe, Model N
Solange Corriol-Rohou is a pulmonologist and an immuno-allergist by training. She joined AstraZeneca R&D in 2004 where she is currently Sr. Director Regulatory Affairs & Policy for Europe. Over the past 18 years, moving from the French Medicines Agency to Pharmaceutical Industry, she has...
Solange Rohou, Senior Director of Regulatory Affairs and Policy for Europe, Astrazeneca R and D
Dr Katja Rudell, Director of Patient Reported Outcomes, Astra Zeneca
Mr. Russell is an internationally known health economist with more than 30 years of experience. During his career he has consulted to more than 60 life sciences companies, including most of the largest global medical device companies, on issues pertaining to clinical and commercial strategy;...
Mr Mason Russell, Solution Lead/Practice Head, Strategic Consulting, Truven Life Sciences, Truven Health Analytics
Peter Rutherford is responsible for strategy and execution of Integrated Market Access and patient centric services within Europe and Emerging Markets for Quintiles. Peter’s background includes twenty-plus years of scientific experience gained from working across academia, industry, payers and...
Professor Peter Rutherford, Vice President, Integrated Market Access, QuintilesIMS
Supriya Saraf is a Senior Engagement Manager at Precision for Value’s Global Pricing & Product Strategy London practice. Supriya has 7 years of consulting experience in the pricing and market access space. Supriya has worked on a variety of engagements including pricing and market access...
Ms Supriya Saraf, Senior Engagement Manager, Precision for Value
Ed Schoonveld is a Principal with ZS Associates in Princeton, NJ and Lead for the firm’s Market Access and Pricing Practice. He has extensive experience in pharmaceutical marketing and pricing from both the corporate pharma and consultancy perspective. He has gained extensive experience in the...
Mr Eltjo Schoonveld, Principal, ZS Associates Inc
Mr Ad Schuurman, Head International Department, National Health Care Institute
Dr. Jitendar Kumar Sharma heads the Healthcare Technology Division at National Health Systems Resource Center, a technical support institution under Ministry of Health & Family Welfare. Since October 2015, he is also Advisor to the government of Andra Pradesh for Health and Medical...
Dr Jitendar Sharma, Head Healthcare Technology, Ministry of Health & Family Welfare
Simon Shohet, Senior Director, Global Market Access and Pricing, Ipsen
Jayne Spink is Chief Executive of the Tuberous Sclerosis Association, the UK charity supporting people affected by the rare condition Tuberous Sclerosis Complex and the UK's only dedicated funder of TSC research. Before joining the TSA, Jayne served as Director of Policy & Research with...
Jayne Spink, Chief Executive Officer, Tuberous Sclerosis Association U.K.
After a short stint in marketing of medical robotics he has spent the last nineteen years inPfizer. Sam is currently Director of Global Pricing. In this role he has led the developmentand implementation of our new pricing system. This incorporates developing their pricinggovernance, policies and...
Mr Sam Taylor, Global Pricing Director, Pfizer
Thomas started his career as a business development manager at a biopharmaceutical startup company, working on 8-digit in- and out-licensing and M&A projects as well as the company’s IPO. In his role as project manager in a strategy consulting firm, he consulted various large German health...
Thomas Temme, Head of Value Demonstration & Access & Public Affairs, Germany, Austria and Switzerland, Shire
Ms Keiko Tone, VP Market Access, Shionogi Limited
Dimitrios Tsourougiannis, Associate Director, EMEA Health Economics & Outcomes Research, Astellas Pharma Europe Ltd
After a short time at the research department of the Belgian construction industry association, Bart joined the department of ‘’Operations Research and Business Statistics’’ at the Faculty of Business and Economics at the University of Leuven where he obtained his PhD in Applied Economics in...
Bart Vermeulen, Deputy Director Healthcare at Office of the Minister of Social Affairs and Public Health, Belgian Federal Government
Bart Vermeulen, Deputy Director Healthcare at Office of the Minister of Social Affairs and Public Health, Belgian Federal Government
Sarah Wamala Andersson has recently served as the Principal Research Scientist (real world evidence) for the Northern European Cluster at Eli Lilly & Company. Sarah has previously worked as a Professor of Health Policy and Karolinska Institutet, Director General (CEO) of the Swedish National...
Dr Sarah Wamala Andersson, Consultant, Real World Evidence and Value-based medicines, Independent
Mr John Wise, Consultant, Pistoia Alliance
In January 2015 Fabrizio joined Swedish Orphan Biovitrum as Director Patient Access, part of the Management Team in the D-A-CH region.In the D-A-CH region, Fabrizio took the responsibility to ensure optimal access to treatment solutions for patients suffering from rare diseases. His main objective...
Fabrizio Zucca, Director Patient Access DACH, Sobi
